One Year Effectiveness Study of Intravitreous Ranibizumab in Neovascular Age ‐Related Macular Degeneration: A Meta‐Analysis

ConclusionThis meta‐analysis suggests visual improvements at 12 months of 0.5‐mg ranibizumab use in patients with wAMD. A higher gain in VA was observed when pooling results from RCTs compared to those in observational studies.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: Original Research Article Source Type: research